Vidac Pharma Holding Plc (ETR:T9G)

Market Cap	23.64M
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	51.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,000
Open	0.4510
Previous Close	0.4580
Day's Range	0.4500 - 0.4510
52-Week Range	0.3500 - 0.9600
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 30, 2026

About Vidac Pharma Holding

Vidac Pharma Holding Plc, an investment holding company, engages in the discovery and development of medicines for oncologic and dermatologic diseases. The company is developing VDA-1102 ointment, an anti-neoplastic agent that is in Phase 2 clinical trials for triggering apoptosis in cancer cells with minimal effects on surrounding normal cells. It is also developing VDA-1102 IV, an anti-neoplastic agent; and VDA-1275, a potent small molecule new chemical entity that are in preclinical stage for use in the treatment of solid tumors. The company...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2021
• Country: United Kingdom
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: T9G

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 24, 2026

Data Sources Report a data error